Liposomal methylene blue hydrogel for selective photodynamic therapy of acne vulgaris

What Was Tested

The paper reports a study of Methylene blue (non-peptide stack partner) in the context of acne, published as a randomized controlled trial.

Photodynamic therapy (PDT) has been proposed as a treatment option for acne vulgaris.

The authors have proposed in this work a liposomal delivery for methylene blue (MB) for selective acne treatment.

Who Took Part

The study group was 13 patients.

PubMed tags the participants as both men and women.

Gel containing LMB was used for treating 13 patients complaining of mild-moderate acne vulgaris once a week for two weeks.

How the Study Was Run

The design is described as randomized and single-blind.

Random assignment meant chance, not the researchers, decided who got Methylene blue (non-peptide stack partner) and who got the comparison, which limits bias.

Only one side, usually the patients, was kept unaware of whether Methylene blue (non-peptide stack partner) was given.

A time span of two weeks appears in the methods.

Pain and local adverse effects were also evaluated.

What Was Measured

Topics PubMed links to this paper include Acne Vulgaris, Hydrogels, Hydrogen-Ion Concentration, Hyperpigmentation, Liposomes, Methylene Blue and Mice.

What This Means in Plain Language

The paper is a randomized and single-blind study of Methylene blue (non-peptide stack partner) in 13 patients in people with acne over two weeks.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 9 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2009 (Journal of drugs in dermatology : JDD), a journal based in United States.

More context: the Methylene blue (non-peptide stack partner) compound page, Acne research.